Abstract:The application of metabolomics in translational research suffers from several technological bottlenecks, such as data reproducibility issues and the lack of standardization of sample profiling procedures. Here, we report an automated high-throughput metabolite array technology that can rapidly and quantitatively determine 324 metabolites including fatty acids, amino acids, organic acids, carbohydrates, and bile acids. Metabolite identification and quantification is achieved using the Targeted Metabolome Batch Quantification (TMBQ) software, the first cross-vendor data processing pipeline. A test of this metabolite array was performed by analyzing serum samples from patients with chronic liver disease (<i>N</i> = 1234). With high detection efficiency and sensitivity in serum, urine, feces, cell lysates, and liver tissue samples and suitable for different mass spectrometry systems, this metabolite array technology holds great potential for biomarker discovery and high throughput clinical testing. Additionally, data generated from such standardized procedures can be used to generate a clinical metabolomics database suitable for precision medicine in next-generation healthcare.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.analchem.0c04686?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.analchem.0c04686</a>.MRM transitions of 3-NPH derivatized metabolites, linearity range, precision, and accuracy (Table S1) (<a class="ext-link" href="/doi/suppl/10.1021/acs.analchem.0c04686/suppl_file/ac0c04686_si_001.xlsx">XLSX</a>)UPLC-MS/MS instrument settings (Table S2). Clinical information on study subjects (Table S3). Stability of derivatized analytes in biological sample matrices stored under −80 °C (Table S4). Metabolites identified by TargetLynx (Table S5). Metabolites identified by TMBQ (Table S6). The relative differences of levels of metabolites (mean ± S.D.) identified by TMBQ and TargetLynx (Table S7). The Pearson correlation coefficients of the same metabolites quantified by TMBQ and TargetLynx (Table S8). Quantification results in normal human serum, urine, feces, mouse liver and HepG2 cell samples (Median ± SE) (Table S9). Detected metabolites in the control and liver disease patients (Table S10). Effect of the concentration and quantity of the 3-nitrophenylhydrazine on the chemical derivatization (Figure S1). Effect of the concentration and quantity of the EDC on the 3-nitrophenylhydrazine derivatization (Figure S2). Effect of reaction temperature on the 3-nitrophenylhydrazine derivatization of some selected metabolites (Figure S3). Effect of reaction time on the 3-nitrophenylhydrazine derivatization of some selected metabolites (Figure S4). Typical TIC chromatograms of all 320 metabolite standards (Figure S5). Typical EIC of organic acid standards (Figure S6). Typical EIC of carbohydrates (Figure S7). Typical EIC of bile acid standards (Figure S8). Typical EIC of fatty acid standards (Figure S9). Typical EIC of amino acids and nucleotides (Figure S10). Typical EIC of short chain fatty acids (Figure S11). Workflow and main features of TMBQ (Figure S12). Fragmentation pattern of butyric acid in ESI negative mode as an example (Figure S13). The real metabolite assay kit of the metabolite array used for the analysis of samples in this study (Figure S14). OPLS-DA scores plots of serum metabolite profiles of the controls and liver disease patients and Pie chart showing the chemical classification of the detected metabolites in liver disease patients (Figure S15). 3D scores plot of serum metabolite profiles of (A) HBV patients, fibrosis and cirrhosis patients, and (B) HCC and ICC patients (Figure S16) (<a class="ext-link" href="/doi/suppl/10.1021/acs.analchem.0c04686/suppl_file/ac0c04686_si_002.pdf">PDF</a>)This article has not yet been cited by other publications.

A convenient and efficient 4-(diethylamino)-butylamine-labeled polarity-response-homodispersed strategy for absolute quantification of carboxyl submetabolome: Monitoring the whole progressive course of hepatocellular carcinoma

Dysregulated Serum Metabolites in Staging of Hepatocellular Carcinoma.

High performance liquid chromatography-mass spectrometry for metabonomics: potential biomarkers for acute deterioration of liver function in chronic hepatitis B.

Study of urinary steroid hormone disorders: difference between hepatocellular carcinoma in early stage and cirrhosis

Metabonomic Profiles Discriminate Hepatocellular Carcinoma from Liver Cirrhosis by Ultraperformance Liquid Chromatography-Mass Spectrometry.

Isotope labelled in suit derivatization-extraction integrated system for amine/phenol submetabolome analysis based on nanoconfinement effect: Application to lung cancer

Accurate determination for lipidomics based on LC-tandem-MS parameters modeling, prediction, and database: Monitoring the progression of hepatocellular carcinoma

Differences between the metabolic profiles of decompensated and compensated cirrhosis patients with Hepatitis B virus infections under high-performance liquid chromatography-mass spectrometry

A Metabolite Array Technology for Precision Medicine

Analysis of Serum Exosome Metabolites Identifies Potential Biomarkers for Human Hepatocellular Carcinoma

Fecal Metabolome Profiling of Liver Cirrhosis and Hepatocellular Carcinoma Patients by Ultra Performance Liquid Chromatography–mass Spectrometry

Serially Coupled Reversed Phase-Hydrophilic Interaction Liquid Chromatography–tailored Multiple Reaction Monitoring, a Fit-for-purpose Tool for Large-Scale Targeted Metabolomics of Medicinal Bile

Serum and Urine Metabolite Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma*

Comprehensive Metabolomic Search for Biomarkers to Differentiate Early Stage Hepatocellular Carcinoma from Cirrhosis

Absolute Quantification of Acylcarnitines Using Integrated Tmt-PP Derivatization-Based LC–MS/MS and Quantitative Analysis of Multi-Components by a Single Marker Strategy

Identification of a novel plasma metabolite panel as diagnostic biomarker for hepatocellular carcinoma

Plasma Lipidomic Analysis to Identify Novel Biomarkers for Hepatocellular Carcinoma

Optimization of metabolomics pretreatment method of cholangiocarcinoma cells based on ultrahigh performance liquid chromatography coupled with mass spectrometry

Diazo-carboxyl click chemistry enables rapid and sensitive quantification of carboxylic acid metabolites

A Chemical Derivatization-Based Pseudotargeted Liquid Chromatography-Tandem Mass Spectrometry Method for Sensitive and High Coverage Determination of Bile Acids in Human Serum

Monitoring One-carbon metabolism by mass spectrometry for early diagnosis of cirrhosis and HCC